You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in France

Apr 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Consumer health registers low but positive value growth in 2011

Consumer health experienced low but positive value sales growth in 2011. In comparison with 2010, there was a slight improvement of overall performance. Some categories of products, such as proton pump inhibitors, antihistamines/allergy remedies (systemic), cranberry, emergency contraception, antiparasitics/lice (head and body) treatments and NRT lozenges, performed well and consequently balanced bad results of other consumer health products, such as those included in weight management.

Ageing population and concentration in urban areas, key growth drivers

The market continued to benefit from changes in the demographic structure of the country and the growing concentration of the population in urban areas, but also from the progressive availability of OTC medicines in the marketplace, some of them switched from the RX market, others due to manufacturers’ investments on new product development. Higher consumer concerns with their health led to a higher demand of more natural products or those helping to reduce consumption of tobacco and consequently also helped to balance negative effects of a poor economic context and expected tightened legislation regarding some categories of consumer health products.

Direct selling and herbal products behind best-performing operators

Around 130 different players were operating within consumer health in 2011. Amongst them, Laboratoires McNeil and Laboratoires UPSA led with a 6% value share each. These operators own a large portfolio of brands, some of them high recognised, and consequently are present in several categories of the market. In 2011, best-performing players were Nu Skin France and Laboratoire Terra Santé BP. The first one is a recent direct selling operator and consequently was able to improve again its weight thanks to its Pharmanex brand. The second one is the owner of Duo LP-Pro, a new generation of antiparasitics/lice (head and body) treatments which are insecticide free.

Pharmacies still the most common retailer for consumer health products

Non-grocery retailers, in particular chemists/pharmacies, remains the most important distribution channel for consumer health products in France, partly because OTC medicines are exclusively available in pharmacies, but also because in order to self-medicate, French consumers continue to be receptive to the advice of pharmacists. In 2011, these retailers lost some weight that was favourable to non-store retailing, namely internet retailing and direct selling. Meantime, the value share of grocery retailers remained stable.

Modest growth expected over the forecast period

Constant value sales of consumer health are forecast to be stable between 2011 and 2016. The majority of the products included within the consumer health industry have already a high penetration in French households, largely because French consumers are already used to self-medicating with them. Even so, some categories of products, such as cranberry and antihistamines/allergy remedies (systemic) will continue to perform well and to boost overall performances. Demand for such products will remain driven by the ageing population that is a source of more potential patients and the growing number of people living in urban areas that have stressful lifestyles. There are also good perspectives for some herbal/traditional products, such as the new generation of antiparasitics/lice (head and body) treatments that are insecticide free. Consumers’ receptivity for such products is expected to increase, as they perceive these products as more natural and consequently prefer them because they are less harmful for health. Meantime, the unfavourable economic context will continue to be a major challenge for manufacturers that sell products considered as less essential, such as weight management ones.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in France with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in France, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in France for free:

The Consumer Health in France market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in France?
  • What are the major brands in France?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in France - Industry Overview

EXECUTIVE SUMMARY

Consumer health registers low but positive value growth in 2011

Ageing population and concentration in urban areas, key growth drivers

Direct selling and herbal products behind best-performing operators

Pharmacies still the most common retailer for consumer health products

Modest growth expected over the forecast period

KEY TRENDS AND DEVELOPMENTS

Hectic lifestyles behind good performances of some categories of OTC drugs

Ageing population a major driver for consumer health

Weight management, the most affected by the weak economic context

Transfer of RX drugs to OTC market continues to boost growth potential

French consumers increasingly receptive to oral NRT smoking cessation aids

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Advertising

Packaging and Labelling

Distribution

Vitamins and dietary supplements registration and classification

EU Legislation

Self-medication/self-care and preventive medicine

Generics

Switches

  • Summary 1 OTC – Switches 2009-2011

DEFINITIONS

SOURCES

  • Summary 2 Research Sources

Consumer Health in France - Company Profiles

Alcon France SA, Laboratoires in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 5 Laboratoires Alcon France SA: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 6 Laboratoires Alcon France SA: Competitive Position 2011

Arkopharma SA, Laboratoires Pharmaceutiques in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 9 Laboratoires Pharmaceutiques Arkopharma SA: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 10 Laboratoires Pharmaceutiques Arkopharma SA: Competitive Position 2011

Bayer Sante Familiale SAS in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 13 Bayer Santé Familiale SAS: Competitive Position 2011

Cooperation Pharmaceutique Francaise SAS (Cooper) in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 16 Cooperation Pharmaceutique Francaise SAS (Cooper): Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 17 Cooperation Pharmaceutique Francaise SAS (Cooper): Competitive Position 2011

Juva Santé, Laboratoires in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 20 Laboratoires Juva Santé: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 21 Laboratoires Juva Santé: Competitive Position 2011

Laboratoires McNeil in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 24 Laboratoires McNeil: Competitive Position 2011

Laboratoires URGO SA in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 27 Laboratoires URGO: Competitive Position 2011

Pierre Fabre SA, Laboratoires in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 30 Laboratoires Pierre Fabre SA: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 31 Laboratoires Pierre Fabre SA: Competitive Position 2011

UPSA, Laboratoires in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 34 Laboratoires UPSA: Production Statistics 2011

COMPETITIVE POSITIONING

  • Summary 35 Laboratoires UPSA: Competitive Position 2011

Adult Mouth Care in France - Category Analysis

HEADLINES

TRENDS

  • Adult mouth care, in France, is characterised by a low number of players, each of them owner of highly recognised brands. Investments in new product development and advertising are limited, largely because the size of the market does not incite stronger manufacturers’ investments. This context was again favourable to both first-ranked Eludril as well as second-ranked Hextril, which both saw their weight reinforced in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires McNeil and Laboratoires Pierre Fabre controlled together 93% of overall current value sales in 2011. Both players owned two well-established and highly recognised adult mouth care brands: Hextril and Alodont for Laboratoires McNeil and Eludril and Pansoral for Laboratoires Pierre Fabre.

PROSPECTS

  • Constant value sales of adult mouth care are forecast to post negative CAGR of -2% over the forecast period. Lack of innovation and advertising, associated with competition from RX medicines as well as mouthwashes/dental rinses will continue to limit performances of this market until 2016.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in France - Category Analysis

HEADLINES

TRENDS

  • Analgesics continued to be OTC medicines with which French consumers do not hesitate to self-medicate. In 2011, acetaminophen and in specific cases ibuprofen and ketoprofen continued to be preferred to aspirin.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires UPSA, with a value share of 29%, and Théraplix with a value share of 28% led analgesics in 2011. Both players were present within acetaminophen, the most valuable category, with highly recognised brands Efferalgan and Defalgan for the former company and Doliprane and Dolitabs for latter one.

PROSPECTS

  • In order to relieve pain, French consumers are expected to continue to buy OTC drugs. In fact, there are low probabilities that for these minor ailments French consumers will go further to the doctor. This is partly because they have increasingly busy lifestyles and no time to do it, but also because reimbursement of these drugs is tending to diminish. Surrounded increasingly with more information, consumers’ confidence in self-medicating with analgesics should continue to grow, in particular when it concerns acetaminophen and ibuprofen drugs.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in France - Category Analysis

HEADLINES

TRENDS

  • In 2011, calming and sleeping OTC medicines continued to benefit from the growing ageing population, as in general, older people tend to suffer more from sleeping disorders and anxiety, but also from increasingly busy lifestyles of an urban and consequently more stressed population.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires UPSA remained the leading player in the calming and sleeping category in 2011 with a 27% value share. This performance was achieved thanks to performances of its highly recognised brand Donormyl. Bayer Santé Familiale followed closely with a 25% value share, thanks to performances of Euphytose medicine. Jolly-Jattel ranked third with its Spasmine Jolly drug. This player controlled a 12% of the total market in value.

PROSPECTS

  • Constant value sales of calming and sleeping OTC medicines are expected to increase at a CAGR of 1% over the forecast period. In order to reduce their stress and sleep disorders, French consumers, in particular old and urban population, are expected to prefer OTC drugs to RX medicines that have more risk of causing addiction.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in France - Category Analysis

HEADLINES

TRENDS

  • In 2011, cough, cold and allergy (hay fever) remedies was essentially driven by performances of antihistamines/allergy remedies (systemic). Hay fever varies according to regions, seasons and weather conditions. Air pollution is considered a major factor for development of this disease. In France, as the majority of the population lives in cities and air pollution is more significant in urban areas, the number of persons suffering from this disease has been increasing over the years. According to trade sources, it is estimated that approximately 10 million French consumers suffer from hay fever. In part stimulated by this high growth potential, some manufacturers have launched new loratadine-based OTC drugs, what also helped to boost sales of this category.

SWITCHES

COMPETITIVE LANDSCAPE

  • More than 20 players are operating within cough, cold and allergy (hay fever) remedies in France. Amongst them, leading operators in 2011 were Laboratoires URGO and Ricola with value shares of 15% and 12% respectively. Laboratoires URGO owns the Humex brand, which offers a large range of OTC medicines and is consequently present in several categories of cough, cold and allergy (hay fever) remedies. Ricola continues to be the leader of medicated confectionery, one of the most valuable categories of cough, cold and allergy (hay fever) remedies.

PROSPECTS

  • Self-medication in terms of cough, cold and allergy (hay fever) remedies should develop further over the forecast period. For minor ailments, people are unlikely to change their habits and go more often to the doctor to have prescription medicines, in part because they need time to do it and time is increasingly missing due to busy lifestyles. Whilst competition from homeopathic products should continue to limit performances of major categories of cough, cold and allergy (hay fever) remedies, antihistamines/allergy remedies (systemic) have still high potential for growth due to a growing number of people that suffer from allergies such as hay fever.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in France - Category Analysis

HEADLINES

TRENDS

  • The transfer of prescription digestive medicines to the self-medication market continued in France between the end of 2010 and 2011. After the switch of Pantoprazole with a dosage of 20mg per tablet at the end of 2009, Trimebutine 100mg was switched at the end of 2010. As a result, new brands were available within this category: Pantozol Control from Nycomed France, Pantoloc from Novartis Group France and Mopralpro from Bayer Santé Familiale, all of them proton pump inhibitors during 2010, but also Décricalm, the IBS treatment from Pfizer Santé Familiale in 2011. If these new brands came to bring some dynamism to this market, they also increased cannibalisation between the different categories of digestive remedies.

SWITCHES

COMPETITIVE LANDSCAPE

  • Digestive remedies is a fragmented category with more than 20 players operating in it. Laboratoires McNeil led with a 12% value share in 2011. This leading operator was present in several categories, in general with highly recognised brands that had a high weight. Laboratoires Céphalon and Théraplix followed with 11% value shares each.

PROSPECTS

  • As proton pump inhibitors are the most recent OTC digestive remedies available in the market, there is still potential for growth over the forecast period. They are expected to continue to drive sales of digestive remedies until 2016.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in France - Category Analysis

HEADLINES

TRENDS

  • In 2011, consumers continued to be receptive to products that clean the ear. In fact, a growing number of French consumers tend to avoid using cotton buds and prefer specific OTC products with reputation of being less harmful.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires Chauvin dominated ear care with a 60% value share in 2011. This company owns several brands within this category, including Cerulyse, which remains the leading OTC ear care brand.

PROSPECTS

  • Constant value sales of ear care are expected to decline at a CAGR of -2% over the forecast period. On one hand, demand is expected not to suffer strong variation between 2011 and 2016. On the other, no major evolution in terms of manufacturers’ investment is forecast. The low growth potential of this category, as well as the small size of the market, will not encourage the pharmaceutical industry to invest in it.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in France - Category Analysis

HEADLINES

TRENDS

  • Current value sales of emergency contraception grew by 9% in 2011. This growth was relatively similar to but slightly lower than the CAGR observed during the review period. Even if there are some reimbursed RX emergency contraception medicines available in the marketplace, to get them women need to visit a doctor beforehand this is not necessarily possible in urgent cases of contraception failure or unprotected sex. As a result, French women continue to purchase OTC emergency contraception drugs to prevent unplanned pregnancies, as they can easily get this type of drug in pharmacies.

SWITCHES

COMPETITIVE LANDSCAPE

  • Two players operate within emergency contraception in France: the leader, European player Laboratoires HRA Pharma, with its NorLevo drug and the domestic player, Laboratoires Biogaran, with its Lévonorgestrel Biogaran medicine.

PROSPECTS

  • Constant value sales of emergency contraception are expected to grow at a CAGR of 5% over the forecast period. To prevent unplanned pregnancies, French women are expected to continue to use this contraceptive method and in urgent cases to prefer to buy them directly in pharmacies than to go to a doctor to have a prescription for reimbursed drugs.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2006-2011
  • Table 54 Sales of Emergency Contraception: % Value Growth 2006-2011
  • Table 55 Emergency Contraception Company Shares by Value 2007-2011
  • Table 56 Emergency Contraception Brand Shares by Value 2008-2011
  • Table 57 Forecast Sales of Emergency Contraception: Value 2011-2016
  • Table 58 Forecast Sales of Emergency Contraception: % Value Growth 2011-2016

Eye Care in France - Category Analysis

HEADLINES

TRENDS

  • Current value sales of eye care increased by 1% in 2011. This performance was relatively in line with that observed during the review period. Eye care is characterised by stability in terms of demand and low manufacturer investment, thus leading to small variations in value sales year after year.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires McNeil with a value share of 29% ranked first in 2011. This position is largely explained by performances of Dacryosérum, the leading standard eye care medicine. Veyron & Froment and Ciba Vision followed with value shares of 13% and 8%, respectively, thanks to performances of Optrex drug for the first one and Vitabact and Unilarm medicines for the second one, all of them also present in standard eye care.

PROSPECTS

  • Constant value sales of eye care are expected to decrease at a CAGR of -1% over the forecast period. No important variation in terms of demand is forecast and main players of this category should maintain low investments. The market should also see further competition from homeopathy remedies, in particular from Homeoptic by Laboratoires Boiron, which will also limit performances over the forecast period.

CATEGORY DATA

  • Table 59 Sales of Eye Care by Category: Value 2006-2011
  • Table 60 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 61 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 62 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 63 Eye Care Company Shares by Value 2007-2011
  • Table 64 Eye Care Brand Shares by Value 2008-2011
  • Table 65 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 66 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in France - Category Analysis

HEADLINES

TRENDS

  • Perceived as more natural and having fewer side effects, herbal/traditional products continued to see increased popularity in 2011. As a result, volume sales increased again, and stimulated current value sales of this market as a whole.

COMPETITIVE LANDSCAPE

  • Ricola with a 15% value share ranked first within herbal/traditional products in 2011. This player ranked second in herbal/traditional cough, cold and allergy (hay fever) remedies, one of the most valuable categories, with its brand Ricola, the leader of medicated confectionery.

PROSPECTS

  • The key story of the forecast period is the growing number of French consumers that are expected to self-medicate with herbal/traditional products because such products are considered as more natural and thus less harmful to health.

CATEGORY DATA

  • Table 67 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 68 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 69 Herbal/Traditional Products Company Shares 2007-2011
  • Table 70 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 71 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 72 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in France - Category Analysis

HEADLINES

TRENDS

  • French consumers are increasingly confident to self-medicate with OTC medicated skin care products, in particular with those that are herbal based. In order to treat minor ailments, they do not want to lose time going to doctors. Even so, some of them still prefer semi-ethical drugs and Rx medicines because they are reimbursed.

SWITCHES

COMPETITIVE LANDSCAPE

  • Medicated skin care is a fragmented consumer health category with more than 30 players operating in it. In 2011, Laboratoires McNeil led with a 15% value share. This player was present in several categories of medicated skin care with different brands, some of them well positioned, such as Gyno-Pévaryl, which dominated vaginal antifungals with 95% of value sales in 2011. Laboratoires Pierre Fabre and Cooper followed with value shares of 8% and 7%, respectively.

PROSPECTS

  • French consumers are expected to self-medicate further with medicated skin care products, in part because they treat minor ailments for which consumers do not want to lose time to see a doctor. The growing availability of products available through self-service will also help to reinforce this trend, as consumers can easily handle and choose the products they need in pharmacies.

CATEGORY DATA

  • Table 73 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 74 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 75 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 76 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 77 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 78 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 79 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in France - Category Analysis

HEADLINES

TRENDS

  • According to trade press, the number of smokers that tried to stop or to reduce their consumption of tobacco increased again between 2010 and 2011. This context was favourable to NRT smoking cessation aids, as in order to stop or reduce smoking, smokers did not hesitate to self-medicate.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires McNeil with a 38% value share led smoking cessation aids in 2011. This player with its Nicorette brand covered the majority of the categories of NRT smoking cessation aids in France. Laboratoires Pierre Fabre followed with a 29% value share. This operator owned three different brands, each of them offering different types of products (Nicogum for gums, Nicopatch for patches and Nicopass for lozenges).

PROSPECTS

  • Several factors are expected to continue to positively impact NRT smoking cessation aids over the forecast period. First, a growing number of smokers is expected to quit smoking or to reduce their consumption, in part because they are not allowed to smoke in public spaces, but also because they are increasingly more concerned about their health and wellbeing. In addition, in order to reduce health costs, the French government should continue to adopt measures to reduce diseases such as cancer and consequently to adopt unfavourable smoking policies. The price of tobacco, for example, is likely to be regularly used as a tool to discourage people to smoke. However, as the number of smokers is expected to decline further in the future (around 9% between 2011 and 2016 according to Euromonitor International), the number of consumers susceptible to using NRT smoking cessation aids will gradually lessen over the years, thus meaning slower volume growth in the future.

CATEGORY INDICATORS

  • Table 80 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 81 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 82 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 83 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 84 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 85 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

Sports Nutrition in France - Category Analysis

HEADLINES

TRENDS

  • Increasingly concerned about their appearance, wellbeing and health, French consumers were increasingly receptive to sports activities in 2011, in particular an urban and young population also looking to relax and have pleasure. Consequently, the base of potential consumers for sports nutrition products continued to rise in the country, boosting volume sales and consequently current value sales of sports nutrition by 5% in 2011, a better performance in comparison to that of the previous year and that of the review period.

COMPETITIVE LANDSCAPE

  • EA Pharma led sports nutrition with a 45% value share in 2011. This player with its two brands (Eafit and Supragen) offered a large range of products covering all consumers’ needs. Eafit continued to be the leading brand of sports nutrition due to its high recognition and a presence in several distribution channels, such as pharmacies. In the second position was Decathlon with its Aptonia brand. This private label offers a large range of sports nutrition products and has strategic position in shelves of Decathlon stores, which allowed this specialist sports retailer to reach a 14% value share.

PROSPECTS

  • Positive growth is expected in the future for sports nutrition due to a higher demand coming from a population that engages in sports, without being professionals. As a result, there is an opportunity to take profit for brands targeting “amateur” athletes who practice physical activities other than the development of their muscles and for products that are less aggressive and with a smaller dosage.

CATEGORY DATA

  • Table 88 Sales of Sports Nutrition: Value 2006-2011
  • Table 89 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 90 Sports Nutrition Company Shares 2007-2011
  • Table 91 Sports Nutrition Brand Shares 2008-2011
  • Table 92 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 93 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in France - Category Analysis

HEADLINES

TRENDS

  • The major story within vitamins and dietary supplements in 2011 continued to be the tightened legislation expected to be implemented in the short term. This changing legislative environment is forecast to create more difficulties in terms of marketing approval and has already started to limit manufacturers’ investment in new product development. As a result, some players continued to reformulate products that are already available in the marketplace whilst others reduced their brands portfolio and focused on their best performers.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Vitamins and dietary supplements is highly fragmented with more than 50 players operating in it. Amongst them, the most important is Laboratoires Arkopharma, with a 13% value share in 2011. This manufacturer was the only one with a value share superior to 10% in that year. Laboratoires Arkopharma was present in several categories of vitamins and dietary supplements with some well-known brands, such as Arkogélules, for example, a well-established brand with a large portfolio of products. The company ranks first in dietary supplements and fourth in vitamins.

PROSPECTS

  • The most important story of the forecast period is the expected to be the evolution in terms of legislation. New requirements should create more barriers to the launch of new products. Meantime, the number of products is expected to diminish, as manufacturers will need to prove the promises they make to consumers on their packaging. This changing legislative framework will be less favourable to small players that have more difficulties to adapt their formulas.

CATEGORY DATA

  • Summary 36 Dietary Supplements: Brand Ranking by Positioning 2011
  • Table 94 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 95 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 96 Dietary Supplements by Positioning 2006-2011
  • Table 97 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 98 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 99 Vitamins Brand Shares by Value 2008-2011
  • Table 100 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 101 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 102 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in France - Category Analysis

HEADLINES

TRENDS

  • Whilst sales of Alli continued to limit performances of other categories within the weight management market, the category overall remained affected by consumer budget restrictions due to low perspectives of purchasing power improvement in the future. In addition, several other factors continued to negatively impact the market, such as the high number of products in the market, some of them unable to fulfil their promises. To counter the unfavourable context and boost their sales, major weight management manufacturers limited their investments in new product development, preferring to focus on brands that had already proven their success. Some of them also tried to cross the bad period by selling their products in a package, including for example physical activity that offers a larger approach in terms of consumers’ diet support.

COMPETITIVE LANDSCAPE

  • More than 20 players were operating within weight management in France during 2011. In this fragmented category, Nutrition & Santé led with a 26% value share. This strong position is largely explained by its leadership within the most valuable category, meal replacement slimming products. Meanwhile, remaining players had value shares of less than 10%.

PROSPECTS

  • Obesity is expected to evolve further in France over the forecast period, thus meaning a higher number of potential buyers for weight management products. However, as French consumers are surrounded by messages that encourage them to control or lose weight through eating healthier and balanced diets and doing exercise, rather than by consuming weight management products, this aspect of the health and wellness trend will have a limited impact in developing of this market. In addition, the economic context is forecast to continue unfavourable, as without the prospect of purchasing power improvement, consumers tend to reduce expenses with these products, as they are not perceived as essential. Weight management manufacturers will also face a growing number of consumers looking for efficacy and products with results that have been already proven.

CATEGORY DATA

  • Table 103 Sales of Weight Management: Value 2006-2011
  • Table 104 Sales of Weight Management: % Value Growth 2006-2011
  • Table 105 Weight Management Company Shares 2007-2011
  • Table 106 Weight Management Brand Shares 2008-2011
  • Table 107 Forecast Sales of Weight Management: Value 2011-2016
  • Table 108 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in France - Category Analysis

HEADLINES

TRENDS

  • In 2011, wound care saw less new product development, particularly within sticking plaster/adhesive bandages, compared to recent previous years, when several new technologies were launched. This lack of dynamism is in part explained by the small size of this market in value terms, which does not allow constant investments in innovation and the need for some time in order to know the results of recent efforts made.

COMPETITIVE LANDSCAPE

  • Laboratoires URGO led wound care with a value share of 33% in 2011. This player with its Urgo range of sticking plasters had a strong presence in pharmacies. Laboratoires Mercurochrome and Beiersdorf (France) followed with value shares of around 22% and 20%, respectively. Both are well represented in main grocery retailers with their brands Laboratoires Mercurochrome and Hansaplast, where they cover all the categories of wound care.

PROSPECTS

  • Over the forecast period, wound care manufacturers are expected to continue to invest essentially within the sticking plasters/adhesive bandages category, through the launch of innovative products that bring more comfort to consumers or are more effective in treating wounds. Some of them could also try to target further niches of the market, such as products for children. This focus is related to the fact that this category is not only the most valuable, but also has the most growth potential.

CATEGORY DATA

  • Table 109 Sales of Wound Care by Category: Value 2006-2011
  • Table 110 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 111 Wound Care Company Shares by Value 2007-2011
  • Table 112 Wound Care Brand Shares by Value 2008-2011
  • Table 113 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 114 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Cranberry
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Lecithin
            • Yeast
            • Other Other Non-Herbal Dietary Supplements
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Paediatric Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Paediatric Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Paediatric Consumer Health
      • Paediatric Analgesics
        • Paediatric Acetaminophen
        • Paediatric Aspirin
        • Paediatric Combination Products - Analgesics
        • Paediatric Diclofenac
        • Paediatric Dipyrone
        • Paediatric Ibuprofen
        • Paediatric Ketoprofen
        • Paediatric Naproxen
      • Paediatric Cough, Cold and Allergy Remedies
        • Paediatric Allergy Remedies
        • Paediatric Cough/Cold Remedies
      • Paediatric Digestive Remedies
        • Paediatric Diarrhoeal Remedies
        • Paediatric Indigestion and Heartburn Remedies
        • Paediatric Laxatives
        • Paediatric Motion Sickness Remedies
      • Paediatric Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Paediatric Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking population - number of adult smokers
  • Smoking prevalence - % of adult population

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!